

![]() |
Choosing wisely: The impact of patient selection on efficacy and safety outcomes in the EINSTEIN-DVT/PE and AMPLIFY trials |
|
Authors | ![]() | |
Published in | Thrombosis Research. 2017, vol. 149, p. 29-37 | |
Abstract | The results of the EINSTEIN-DVT/PE and AMPLIFY trials, which compared rivaroxaban and apixaban with conventional anticoagulation therapy for acute venous thromboembolism (VTE), respectively, are often compared. However, the trials differed in duration of therapy (3-12 and 6months, respectively) and in patient selection (few exclusion criteria and more stringent exclusion criteria, respectively). | |
Keywords | Adult — Aged — Cohort Studies — Factor Xa Inhibitors/administration & dosage/adverse effects/therapeutic use — Female — Hemorrhage/chemically induced — Humans — Male — Middle Aged — Patient Selection — Pyrazoles/administration & dosage/adverse effects/therapeutic use — Pyridones/administration & dosage/adverse effects/therapeutic use — Rivaroxaban/administration & dosage/adverse effects/therapeutic use — Treatment Outcome — Venous Thromboembolism/drug therapy | |
Identifiers | PMID: 27886530 | |
Full text | ||
Structures | ||
Research group | La maladie thromboembolique veineuse (808) | |
Citation (ISO format) | BEYER-WESTENDORF, Jan et al. Choosing wisely: The impact of patient selection on efficacy and safety outcomes in the EINSTEIN-DVT/PE and AMPLIFY trials. In: Thrombosis Research, 2017, vol. 149, p. 29-37. doi: 10.1016/j.thromres.2016.11.014 https://archive-ouverte.unige.ch/unige:101427 |